News Center

On August 2nd, 2021, LaNova Medicines moved to its brand-new office at 999 Cailun Road on Jinke Road in Zhangjiang Science Park, with expanded laboratory and office space. More than 40 employees gathered together in the hall of the new office, and the fou

LM-102 received China NMPA approval for its China phase I/II clinical study.

LM-102 obtained FDA clinical trial approval early this year as a phase I clinical study designed to evaluate the safety and initial efficacy of LM-102.

Claudin 18.2 ADC LM-302 obtained US FDA clinical study approval. This study is a multi-center clinical study designed to evaluate the safety and initial efficacy of LM-302.

Claudin 18.2 ADC LM-302 obtained FDA Orphan Drug Designation in May 2021 for indications of pancreatic, gastric, and gastroesophageal junction cancers.

In November 2020, LaNova Medicines completed the series A financing with Qiming Venture Partners as the leading investor and China Renaissance as the financial adviser. Investors also include global or domestic well-known PE / VCs, such as TF Capital, Yin